DigiBio

Digital biomarkers for patient-reported research

DigiBio builds a research platform for gathering patient-reported outcomes and digital biomarkers. Its customers are biopharmaceutical companies, research institutes and physicians, who rely on it to collect health information from people as they go about daily life. The platform is designed for clinical trials and for research in any therapeutic area.

The company describes its approach as combining active and passive data collection. Participants answer surveys on a smartphone app, while objective measures are captured alongside them, so researchers can compare traditional assessments with data recorded in everyday settings.

How studies use the app

Researchers use the app to deliver materials to study participants at home, such as guided meditations for people in a cancer trial. The app records how often participants open the intervention, which the company says is more reliable than handwritten logs, and it asks short survey questions before and after each session so that immediate effects can be measured. The platform also supports surveys in group programs, such as classes for chronic back pain, where it gives researchers a consistent record of participants' reported pain over the course.

Why research teams adopt it

The company says the platform is HIPAA-compliant and cloud-based, with mobile and web access. It says the platform can be used across all clinical trials and therapeutic areas. It says this reduces the time needed to design, run and manage trials while lowering trial costs and improving data quality. The benefits it lists include continuous real-time data collection, more frequent measurement, higher ecological validity because responses come from real life, and better participant engagement.

Recognition and funding

The company's news pages link its early success to support from the Indiana CTSI. It also reports a new funding call that the institute supported and a place in the last stage of the Indiana Inject Tech Challenge.